137 related articles for article (PubMed ID: 21491823)
1. Tibolone vaginal versus per os administration in the management of post-menopausal symptoms.
Zervoudis S; Iatrakis G; Peitsidis P; Tsikouras P; Galazios G; Liberis V; Navrozoglou I; Ceauşu I; Badiu C
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):471-7. PubMed ID: 21491823
[TBL] [Abstract][Full Text] [Related]
2. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
3. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
5. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
6. Dose-response analysis of effects of tibolone on climacteric symptoms.
Landgren MB; Bennink HJ; Helmond FA; Engelen S
BJOG; 2002 Oct; 109(10):1109-14. PubMed ID: 12387462
[TBL] [Abstract][Full Text] [Related]
7. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
8. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day.
Landgren MB; Helmond FA; Engelen S
Maturitas; 2005 Mar; 50(3):222-30. PubMed ID: 15734603
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.
Bai W; Henneicke-von Zepelin HH; Wang S; Zheng S; Liu J; Zhang Z; Geng L; Hu L; Jiao C; Liske E
Maturitas; 2007 Sep; 58(1):31-41. PubMed ID: 17587516
[TBL] [Abstract][Full Text] [Related]
10. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
11. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
12. The need for tissue selective menopausal agents.
Eden J
Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():22-7. PubMed ID: 16112952
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial.
Morais-Socorro M; Cavalcanti MA; Martins R; Neto Francisco P; Rezende A; Azevedo G; Almeida M
Gynecol Endocrinol; 2012 Jun; 28(6):483-7. PubMed ID: 22132809
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women.
Cayan F; Dilek U; Pata O; Dilek S
J Sex Med; 2008 Jan; 5(1):132-8. PubMed ID: 17961145
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Diaby V; Perreault S; Lachaine J
Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
[TBL] [Abstract][Full Text] [Related]
18. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women.
Rymer J; Robinson J; Fogelman I
Climacteric; 2002 Dec; 5(4):390-8. PubMed ID: 12626219
[TBL] [Abstract][Full Text] [Related]
19. [The influence of a tibolone therapy on endometrium in postmenopausal women].
Szlendak-Sauer K; Wierzba W; Radowicki S
Ginekol Pol; 2008 Nov; 79(11):758-61. PubMed ID: 19140498
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.
Hammar M; Christau S; Nathorst-Böös J; Rud T; Garre K
Br J Obstet Gynaecol; 1998 Aug; 105(8):904-11. PubMed ID: 9746385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
